Bristol-Myers Squibb Buys Cardioxyl Pharmaceuticals

  • Posted on:
  • Posted in: news
Featured image

Congratulations to Dr. John Toscano, Professor of Chemistry and also now Vice-Dean for Research of the Krieger School of Arts & Sciences! The company he developed from his own research on the chemistry of nitroxyl (HNO), Cardioxyl Pharmaceuticals, was just recently acquired by Bristol-Myers Squibb biopharamaceuticals. The company, co-founded with David Kass and Nazareno Paolocci of the School of Medicine, was purchased for $300 million, and the total value could exceed $2 billion depending on future development and sales of CXL-1427, an intravenous treatment for acute decompensated heart failure.

The acquisition was also featured in the Spring 2016 Issue of Arts & Sciences Magazine.